These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Effectiveness of mandatory transmissible diseases screening in Indian blood donors. Choudhury N; Ramesh V; Saraswat S; Naik S Indian J Med Res; 1995 Jun; 101():229-32. PubMed ID: 7672831 [TBL] [Abstract][Full Text] [Related]
28. The usefulness of surrogate markers anti-HBc and ALT for post-transfusion non-A, non-B hepatitis prevention. Richard D J Virol Methods; 1987 Aug; 17(1-2):105-17. PubMed ID: 3117828 [TBL] [Abstract][Full Text] [Related]
29. Post-transfusion non-A, non-B hepatitis: significance of raised ALT and anti-HBc in blood donors. Biswas R Vox Sang; 1989; 56(1):63. PubMed ID: 2492703 [No Abstract] [Full Text] [Related]
30. [Hepatitis C and ALT in blood donors]. García Bueno MJ Sangre (Barc); 1991 Jun; 36(3):252-3. PubMed ID: 1948551 [No Abstract] [Full Text] [Related]
31. Post-transfusion viral hepatitis and the TTVS. Holland PV; Bancroft W; Zimmerman H N Engl J Med; 1981 Apr; 304(17):1033-5. PubMed ID: 6782483 [No Abstract] [Full Text] [Related]
32. Serum bile acids and alanine aminotransferase concentrations. Comparison of efficacy as indirect means of identifying carriers of non-A, non-B hepatitis agents and of onset, severity, and duration of posttransfusion non-A, non-B hepatitis in recipients. Mishler JM; Barbosa L; Mihalko LJ; McCarter H JAMA; 1981 Nov; 246(20):2340-4. PubMed ID: 6795368 [TBL] [Abstract][Full Text] [Related]
33. Post-transfusion non-A, non-B hepatitis: significance of raised ALT and anti-HBc in blood donors. Gillon J; Hussey AJ; Howe SP; Beckett GJ; Prescott RJ Vox Sang; 1988; 54(3):148-53. PubMed ID: 3130726 [TBL] [Abstract][Full Text] [Related]
34. Relation between donor transaminase and recipient hepatitis non-A, non-B in Sweden. Widell A; Sundström G; Hansson BG; Fex G; Moestrup T; Nordenfelt E Vox Sang; 1988; 54(3):154-9. PubMed ID: 3130727 [TBL] [Abstract][Full Text] [Related]
35. The declining risk of post-transfusion hepatitis C virus infection. Donahue JG; Muñoz A; Ness PM; Brown DE; Yawn DH; McAllister HA; Reitz BA; Nelson KE N Engl J Med; 1992 Aug; 327(6):369-73. PubMed ID: 1320736 [TBL] [Abstract][Full Text] [Related]
36. Relationship between guanase activity in donor blood and the incidence of posttransfusional non-A, non-B hepatitis, and a possible method for preventing posttransfusional hepatitis. Ito S; Tsuji Y; Iwasaki A; Kitagawa N; Tamura Y; Fujii S Hepatology; 1986; 6(5):990-3. PubMed ID: 3093359 [TBL] [Abstract][Full Text] [Related]
37. Clinical value of the guanase screening test in donor blood for prevention of posttransfusional non-A, non-B hepatitis. Ito S; Tsuji Y; Kitagawa N; Akihiko I; Syundo J; Tamura Y; Kishi S; Mori H Hepatology; 1988; 8(2):383-4. PubMed ID: 3128469 [TBL] [Abstract][Full Text] [Related]
38. Surrogate testing for non-A, non-B hepatitis in Queensland, Australia: an ALT microtitre tray method for screening blood donors. Hyland CA; Douglas R; Mazzocchi R; Young IF Pathology; 1988 Jul; 20(3):271-4. PubMed ID: 3144700 [TBL] [Abstract][Full Text] [Related]